TMB has emerged as a potential factor associated with immune checkpoint blockade treatment across solid tumor Here we further evaluated the threshold of TMB based on TMB value in our cohort and compar

The findings of this study suggest that a high tumor mutational burden (TMB>1) is associated with shorter overall survival (OS) in patients receiving immune checkpoint blockade treatment for solid tumors. However, there was no significant difference in progression-free survival (PFS) between patients with TMB>1 and TMB<1.

Additionally, the study found that patients with HRD-positive tumors, as indicated by an HRD score of 42 or higher, had worse PFS compared to patients with HRD-negative tumors. However, there was no significant difference in OS between these two groups.

These results suggest that TMB and HRD status may be useful prognostic factors in determining treatment outcomes for patients receiving immune checkpoint blockade or platinum-based chemotherapy/PARP inhibitor therapy, respectively. Further research is needed to validate these findings and explore potential mechanisms underlying these associations